capecitabine + docetaxel + epidoxorubicin + pegfilgrastim

This is a combination regimen consisting of four drugs used primarily in the treatment of certain cancers, particularly breast cancer. The components are: - **Capecitabine** is an oral prodrug that is converted to 5-fluorouracil (5-FU) in the body, inhibiting thymidylate synthase and interfering with DNA synthesis and repair. - **Docetaxel** is a taxane-class chemotherapeutic agent that promotes microtubule assembly while inhibiting their disassembly, leading to cell cycle arrest and apoptosis. - **Epidoxorubicin** (also known as epirubicin) is an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals causing cytotoxicity. - **Pegfilgrastim** is a long-acting form of recombinant human granulocyte colony-stimulating factor (G-CSF), which stimulates the bone marrow to produce neutrophils. It reduces the risk of infection due to chemotherapy-induced neutropenia by binding to the G-CSF receptor on hematopoietic cells[1][2][3]. This combination leverages multiple mechanisms for antitumor activity while using pegfilgrastim for supportive care to mitigate chemotherapy-induced neutropenia.